NCT06618833

Brief Summary

Atrial fibrillation is the most common arrhythmia with a prevalence of 1 to 4% and constitutes a major health problem both on an individual level (impaired quality of life, heart failure, stroke, hospitalization, excess mortality) and collective level (cost, use of resources). Non-medical determinants influence health, particularly its cardiovascular component, but have been little studied in the context of Atrial fibrillation. The rare studies addressing the subject suggest that they impact the incidence of the disease and the occurrence of its complications. Certain social and sociological characteristics are also associated with less access to the various recognized therapies, whether medicinal or invasive. This is the case for Atrial fibrillation ablation, which has nevertheless demonstrated its usefulness in reducing the Atrial fibrillation burden, in reducing symptoms and hospitalizations and for certain populations (heart failure) a decrease in mortality. Essien et al in a literature review report that non-Caucasian and low-income people have less access to Atrial fibrillation ablation. Non-Caucasian populations are also under-represented in interventional clinical studies on Atrial fibrillation. If the level of education (health literacy), geographic origin (rural vs. urban) and the level of isolation affect the occurrence of Atrial fibrillation and its natural history, including complications, the authors do not mention any specific study that has evaluated their role in access to ablation. A Norwegian national analysis (Olsen) based on data from the health system, therefore exhaustive, evaluated the characteristics of patients suffering from Atrial fibrillation and having benefited from ablation compared to the characteristics of patients treated medically. Patients with the highest levels of education and income are the most likely to be treated by ablation. Women, especially at younger ages, have less access to ablation. The authors also found significant differences between the different territorial subdivisions of the country.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 22, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 23, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 1, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

October 1, 2024

Status Verified

September 1, 2024

Enrollment Period

5 months

First QC Date

September 23, 2024

Last Update Submit

September 26, 2024

Conditions

Keywords

Medical and Sociological Characterization of the PopulationGlobal Promis Questionnaire

Outcome Measures

Primary Outcomes (1)

  • Collection of medical and sociological data from the population of patients admitted for a first Atrial Fibrillation Ablation

    Collection of medical data (cardiological, comorbidities, physical and mental health via PROMIS global questionnaire) and sociological data (territorial, economic, professional, ethnic, family). The PROMIS GLOBAL questionnaire is a questionnaire to collect data on the patient's general health. It is presented in 10 questions. The answers can vary between "Excellent to Poor", "Totally to Not at All", "Never to Always" or even "None to Very Intense"

    2 months

Study Arms (1)

Patient admitted for first atrial fibrillation ablation

EXPERIMENTAL
Other: Collection of medical dataBehavioral: Collection of global health elementsBehavioral: PROMIS global questionnaireBehavioral: Collection of sociological data

Interventions

Collection of medical data focused on the history of atrial fibrillation by the principal investigator

Patient admitted for first atrial fibrillation ablation

Collection of global health elements (physical and mental) by the principal investigator by discussion with the patient

Patient admitted for first atrial fibrillation ablation

The patient completes the global PROMIS questionnaire which collects data on their overall health. The questionnaire consists of 10 questions about the patient\'s overall health, and for each question, the patient has a possible choice of 5 answers varying between different propositions depending on the question: Excellent to poor or Totally to not at all, or Always to never or None to very intense

Patient admitted for first atrial fibrillation ablation

Collection of patient sociological data (territorial, economic, professional, ethnic) by the principal investigator

Patient admitted for first atrial fibrillation ablation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients admitted for first ablation of Atrial Fibrillation

You may not qualify if:

  • Patients under 18 years of age
  • Pregnancy
  • No coverage by the French health system
  • Refusal to consent
  • History of left atrium ablation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Clinique Pasteur

Toulouse, 31000, France

RECRUITING

Rangueil Hospital

Toulouse, 31059, France

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Alexandre DUPARC, MD

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alexandre DUPARC, MD

CONTACT

Olivier LAIREZ, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2024

First Posted

October 1, 2024

Study Start

July 22, 2024

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

October 1, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations